Evolving Concept of Severe Asthma: Transition From Diagnosis to Treatable Traits
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, So-Young | - |
dc.contributor.author | Kang ,Sung-Yoon | - |
dc.contributor.author | Song, Woo-Jung | - |
dc.contributor.author | Kim, Joo-Hee | - |
dc.date.accessioned | 2022-10-19T00:40:06Z | - |
dc.date.available | 2022-10-19T00:40:06Z | - |
dc.date.created | 2022-10-04 | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85785 | - |
dc.description.abstract | In recent decades, the concept of severe asthma has evolved from an umbrella term encompassing patients with high-intensity treatment needs to a clinical syndrome with heterogeneous, albeit distinct, pathophysiological processes. Biased and unbiased cluster approaches have been used to identify several clinical phenotypes. In parallel, cellular and molecular approaches allow for the development of biological therapies, especially targeting type 2 (T2) cytokine pathways. Although T2-biologics have significantly improved clinical outcomes for patients with severe asthma in real-world practice, questions on the proper use of biologics remain open. Furthermore, a subset of severe asthma patients remains poorly controlled. The unmet needs require a new approach. The “treatable traits” concept has been suggested to address a diversity of pathophysiological factors in severe asthma and overcome the limitations of existing treatment strategies. With a tailored therapy that targets the treatable traits in individual patients, better personalized medical care and outcomes should be achieved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한천식알레르기학회 | - |
dc.relation.isPartOf | Allergy, Asthma & Immunology Research | - |
dc.title | Evolving Concept of Severe Asthma: Transition From Diagnosis to Treatable Traits | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000863429500003 | - |
dc.identifier.doi | 10.4168/aair.2022.14.5.447 | - |
dc.identifier.bibliographicCitation | Allergy, Asthma & Immunology Research, v.14, no.5, pp.447 - 464 | - |
dc.identifier.kciid | ART002883476 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85144643721 | - |
dc.citation.endPage | 464 | - |
dc.citation.startPage | 447 | - |
dc.citation.title | Allergy, Asthma & Immunology Research | - |
dc.citation.volume | 14 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Kang ,Sung-Yoon | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Asthma | - |
dc.subject.keywordAuthor | biological products | - |
dc.subject.keywordAuthor | endophenotypes | - |
dc.subject.keywordAuthor | precision medicine | - |
dc.subject.keywordAuthor | cytokines | - |
dc.subject.keywordAuthor | outcomes | - |
dc.subject.keywordAuthor | biologics | - |
dc.subject.keywordAuthor | omics | - |
dc.subject.keywordPlus | INHALED CORTICOSTEROIDS | - |
dc.subject.keywordPlus | CLUSTER-ANALYSIS | - |
dc.subject.keywordPlus | LARYNGEAL DYSFUNCTION | - |
dc.subject.keywordPlus | AIRWAY INFLAMMATION | - |
dc.subject.keywordPlus | SUPER-RESPONDER | - |
dc.subject.keywordPlus | ALLERGIC-ASTHMA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | MEPOLIZUMAB | - |
dc.subject.keywordPlus | OMALIZUMAB | - |
dc.subject.keywordPlus | PHENOTYPES | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.